However, in tumor samples from late-stage ovarian cancer patients (III, Mets), SMARCE1 expression increased and was highest in tumors invading into regional lymph nodes and distant organs (Fig. 2 B, Right and SI Appendix, Fig. S1). Here, SMARCE1 is linked to ovarian carcinoma.